EX-99.1 2 d482375dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Contact:

Randle Reece

Director, Investor Relations

866.861.3229

 

 

AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2017 RESULTS

Quarterly revenue of $494 million;

GAAP EPS of $0.57 and adjusted EPS of $0.63

SAN DIEGO – (November 2, 2017) – AMN Healthcare Services, Inc. (NYSE: AMN), healthcare’s leader and innovator in workforce solutions and staffing services, today announced its third quarter 2017 financial results. Financial highlights are as follows:

Dollars in millions, except per share amounts.

 

     Q3 2017      % Change
Q3 2016
    YTD Sept.
30, 2017
     % Change
YTD Sept.
30, 2016
 

Revenue

   $ 494.4        5   $ 1,479.4        5

Gross profit

   $ 159.5        3   $ 482.3        5

Net income

   $ 28.1        3   $ 91.4        15

Diluted EPS

   $ 0.57        4   $ 1.85        15

Adj. diluted EPS*

   $ 0.63        2   $ 1.93        6

Adjusted EBITDA*

   $ 61.7        6   $ 192.0        9

 

* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Supplemental Financial and Operating Data” for a reconciliation of non-GAAP items.

Highlights

 

    AMN’s workforce solutions leadership position continues to grow, with significant new MSP relationships added.

 

    Nurse and Allied grew revenue 6% year over year.

 

    Locum Tenens returned to growth with revenue rising 3% year over year.

 

    Operating cash flow of $26 million in the quarter and $96 million year to date.

 

    Repurchased 177,143 shares in the quarter for $7 million, with an average price per share of $38.18.


“Superior service and a comprehensive suite of workforce solutions continue to differentiate AMN Healthcare and deliver incremental value for healthcare organizations during a time of significant transformation. Our healthcare clients benefit from AMN solutions for hiring great talent, maintaining greater flexibility, using analytics for insight, and ensuring quality patient care,” said Susan R. Salka, President and Chief Executive Officer of AMN Healthcare. “I am proud of our team’s execution in delivering another quarter of solid performance.”

“Market conditions support continued growth, which is bolstered by gains in MSP and other strategic offerings. Key long-term trends remain in our favor and are expected to increase clients’ need for innovative workforce solutions. These factors give us confidence that AMN Healthcare can maintain or improve revenue growth in 2018,” added Ms. Salka.

Third Quarter 2017 Results

Consolidated revenue for the quarter was $494 million, a 5% increase over prior year and 1% higher than the second quarter of 2017. We estimate that less than $2 million of revenue was lost in the quarter due to disruptions associated with the hurricanes.

Revenue for the Nurse and Allied Solutions segment was $303 million, higher by 6% year over year and up 1% sequentially. The Travel Nurse division continued to perform well, with revenue up 5% year over year and flat sequentially. Allied division revenue increased 6% year over year and was down slightly sequentially.

Locum Tenens Solutions segment revenue was $111 million, up 3% both year-over-year and on a sequential basis. Other Workforce Solutions segment revenue was $80 million, reflecting an increase of 4% year over year and down 1% sequentially, with year-over-year growth driven by the VMS and interim leadership businesses, partially offset by declines in the permanent placement businesses.

Gross margin was 32.3%, lower by 40 basis points year over year and 60 basis points sequentially. The year-over-year gross margin decline was due primarily to higher physician pay rates in Locum Tenens and and lower permanent placement fees. The sequential gross margin decline was driven primarily by higher health insurance costs and lower permanent placement fees.

 

2


SG&A expenses were $101 million, or 20.3% of revenue, compared to $100 million, or 21.2% of revenue, in the same quarter last year. Expenses as a percentage of revenue decreased year over year due to improved operating leverage. SG&A was $97 million, or 19.7% of revenue, in the previous quarter, including a $4 million favorable professional liability actuarial adjustment.

Net income was $28 million, or $0.57 per diluted share, compared to $27 million, or $0.55 per diluted share, in the same quarter last year. Excluding amortization of intangible assets, acquisition and integration costs, net of tax, adjusted net income per diluted share was $0.63. Adjusted EBITDA was $62 million, a year-over-year increase of 6%. Adjusted EBITDA margin was 12.5%, representing a 20 basis point increase year-over-year and 120 basis point decline on a sequential basis.

At September 30, 2017, cash and cash equivalents totaled $20 million. For the quarter ended September 30, 2017, cash flow from operations was $26 million and capital expenditures were $5 million. The Company ended the quarter with total debt outstanding of $325 million, with a leverage ratio as calculated in accordance with the Company’s credit agreement of 1.3 to 1.

During the third quarter of 2017, the Company repurchased 177,143 shares of our common stock at an average price of $38.18 per share, resulting in an aggregate purchase price of $7 million. Since the November 2016 inception of our $150 million share repurchase plan, a total of 629,896 shares have been repurchased at an average price of $32.29, with a total of purchase price of $20 million.

 

3


Fourth-Quarter 2017 Outlook

 

Metric

  

Guidance*

Consolidated revenue

   $498 - $504 M

Gross margin

   32.0%

SG&A as percentage of revenue

   20.0%

Adjusted EBITDA margin

   12.0-12.5%

 

* Note: Guidance percentage metrics are approximate. For a reconciliation of adjusted EBITDA margin, see the table entitled “Reconciliation of Guidance Adjusted EBITDA Margin to Guidance Operating Margin” below.

On an as-reported basis, the projected year-over-year growth rate is 2-3%. Excluding any labor disruption revenue, the fourth quarter is expected to reflect year-over-year growth of approximately 5%. The hurricanes are expected to have a negative revenue impact of less than $2 million. The expected sequential decrease in gross margin reflects the normal seasonal margin decline in the Nurse and Allied segment and an unfavorable segment mix shift. Travel Nurse Staffing, our largest business, is expected to grow revenue 6-7% year over year with strong sequential growth of 4-5%.

 

4


Conference Call on November 2, 2017

AMN Healthcare Services, Inc. (NYSE: AMN), healthcare’s leader and innovator in workforce solutions and staffing services, will host a conference call to discuss its third quarter 2017 financial results on Thursday, November 2, 2017 at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through AMN Healthcare’s website at http://amnhealthcare.investorroom.com/presentations. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Interested parties may participate live via telephone by dialing (800) 230-1059 in the U.S. or (612) 234-9959 internationally. Following the conclusion of the call, a replay of the webcast will be available at the Company’s website. Alternatively, a telephonic replay of the call will be available starting at 7:30 p.m. Eastern Time on November 2, 2017, and can be accessed until 11:59 p.m. Eastern Time on November 16, 2017 by calling (800) 475-6701 in the U.S. or (320) 365-3844 internationally, with access code 431402.

About AMN Healthcare

AMN Healthcare is the leader and innovator in healthcare workforce solutions and staffing services to healthcare facilities across the nation. The Company provides unparalleled access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN delivers managed services programs, healthcare executive search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, medical coding and consulting, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities and many other healthcare settings.

The Company’s common stock is listed on the New York Stock Exchange under the symbol “AMN.” For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication (“RSS”) as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://amnhealthcare.investorroom.com/emailalerts.

 

5


Non-GAAP Measures

This earnings release contains certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company’s condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin and (3) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful both to management and investors as a supplement, and not as a substitute, when evaluating the Company’s operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions and allocating resources. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company’s performance. A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled “Supplemental Financial and Operating Data” under the caption entitled “Reconciliation of Non-GAAP Items” and the footnotes thereto or on the Company’s website at http://amnhealthcare.investorroom.com/financialreports. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company’s website.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial performance, our guidance for fourth quarter 2017 revenue, gross margin, SG&A expenses as a percentage of revenue, adjusted EBITDA margin, increases in clients’ need for innovative workforce solutions and our ability to maintain or improve revenue growth in 2018. The Company bases these forward-looking

 

6


statements on its current expectations, estimates and projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimates,” variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Factors that could cause actual results to differ from those implied by the forward-looking statements contained in this press release are set forth in our fillings with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K for the year ended December 31, 2016, our subsequent Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:

Randle Reece

Director, Investor Relations

866.861.3229

 

7


AMN Healthcare Services, Inc.

Condensed Consolidated Statements of Comprehensive Income

(in thousands, except per share amounts)

(unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 30,     June 30,     September 30,  
     2017     2016     2017     2017     2016  

Revenue

   $ 494,406     $ 472,636     $ 489,803     $ 1,479,378     $ 1,414,367  

Cost of revenue

     334,867       318,169       328,791       997,051       953,249  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     159,539       154,467       161,012       482,327       461,118  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross margin

     32.3     32.7     32.9     32.6     32.6

Operating expenses:

          

Selling, general and administrative (SG&A)

     100,579       99,995       96,673       299,325       297,359  

SG&A as a % of revenue

     20.3     21.2     19.7     20.2     21.0

Depreciation and amortization

     8,132       7,789       7,959       23,759       21,888  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     108,711       107,784       104,632       323,084       319,247  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations

     50,828       46,683       56,380       159,243       141,871  

Operating margin (1)

     10.3     9.9     11.5     10.8     10.0

Interest expense, net, and other

     4,837       3,016       4,928       14,895       9,065  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     45,991       43,667       51,452       144,348       132,806  

Income tax expense

     17,863       16,371       20,197       52,957       53,319  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 28,128     $ 27,296     $ 31,255     $ 91,391     $ 79,487  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income as a % of revenue

     5.7     5.8     6.4     6.2     5.6

Other comprehensive income (loss):

          

Foreign currency translation and other

     (73     40       (41     (111     165  

Cash flow hedge, net of income taxes

     —         231       (58     (15     (343
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     (73     271       (99     (126     (178

Comprehensive income

   $ 28,055     $ 27,567     $ 31,156     $ 91,265     $ 79,309  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income per common share:

          

Basic

   $ 0.59     $ 0.57     $ 0.65     $ 1.91     $ 1.66  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

   $ 0.57     $ 0.55     $ 0.63     $ 1.85     $ 1.61  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average common shares outstanding:

          

Basic

     47,912       48,049       47,916       47,870       47,993  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

     49,445       49,410       49,475       49,480       49,287  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

8


AMN Healthcare Services, Inc.

Supplemental Financial and Operating Data

(dollars in thousands, except per share data and operating data)

(unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 30,     June 30,     September 30,  
     2017     2016     2017     2017     2016  

Revenue

          

Nurse and allied solutions

   $ 302,933     $ 286,810       300,727       917,183       877,197  

Locum tenens solutions

     111,415       108,553       108,215       322,473       320,420  

Other workforce solutions

     80,058       77,273       80,861       239,722       216,750  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
   $ 494,406     $ 472,636       489,803       1,479,378       1,414,367  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Reconciliation of Non-GAAP Items:

          

Segment operating income (2)

          

Nurse and allied solutions

   $ 40,807     $ 37,396       47,851       134,638       118,517  

Locum tenens solutions

     14,438       14,026       12,371       39,028       43,634  

Other workforce solutions

     19,890       20,867       22,041       61,788       56,311  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     75,135       72,289       82,263       235,454       218,462  

Unallocated corporate overhead

     13,438       14,235       15,080       43,409       42,460  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA (3)

     61,697       58,054       67,183       192,045       176,002  

Adjusted EBITDA margin (4)

     12.5     12.3     13.7     13.0     12.4

Depreciation and amortization

     8,132       7,789       7,959       23,759       21,888  

Share-based compensation

     2,477       2,704       2,562       7,720       8,795  

Acquisition and integration costs

     260       878       282       1,323       3,448  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations

     50,828       46,683       56,380       159,243       141,871  

Interest expense, net, and other

     4,837       3,016       4,928       14,895       9,065  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     45,991       43,667       51,452       144,348       132,806  

Income tax expense

     17,863       16,371       20,197       52,957       53,319  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 28,128     $ 27,296       31,255       91,391       79,487  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

GAAP diluted net income per share (EPS)

   $ 0.57     $ 0.55       0.63       1.85       1.61  

Adjustments:

          

Amortization of intangible assets

     0.09       0.09       0.09       0.28       0.28  

Acquisition and integration costs

     0.01       0.02       0.01       0.03       0.07  

Tax effect on above adjustments

     (0.04     (0.04     (0.04     (0.12     (0.14

Excess tax benefits (5)

     0.00       0.00       (0.02     (0.11     0.00  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted diluted EPS (6)

   $ 0.63     $ 0.62       0.67       1.93       1.82  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

9


     Three Months Ended     Nine Months Ended  
     September 30,     June 30,     September 30,  
     2017     2016     2017     2017     2016  

Gross Margin

          

Nurse and allied solutions

     27.3     26.7     27.8     27.6     26.7

Locum tenens solutions

     30.1     31.2     30.0     30.2     31.2

Other workforce solutions

     54.1     56.7     55.7     54.9     58.6

Operating Data:

          

Nurse and allied solutions

          

Average healthcare professionals on assignment (7)

     8,817       8,458       8,776       8,881       8,423  

Locum tenens solutions

          

Days filled (8)

     58,881       59,612       58,660       172,784       178,846  

Revenue per day filled (9)

   $ 1,892     $ 1,821     $ 1,845     $ 1,866     $ 1,792  

 

     As of September 30,      As of June 30,
     2017      2016      2017

Leverage ratio (10)

     1.3        1.7      1.4

 

10


AMN Healthcare Services, Inc.

Condensed Consolidated Balance Sheets

(dollars in thousands)

(unaudited)

 

     September 30,      June 30,      December 31,  
     2017      2017      2016  

Assets

        

Current assets:

        

Cash and cash equivalents

   $ 19,625      $ 22,878      $ 10,622  

Accounts receivable, net

     343,596        334,597        341,977  

Accounts receivable, subcontractor

     37,200        36,631        49,233  

Prepaid and other current assets

     42,052        46,938        48,796  
  

 

 

    

 

 

    

 

 

 

Total current assets

     442,473        441,044        450,628  

Restricted cash, cash equivalents and investments

     34,380        33,882        31,287  

Fixed assets, net

     68,188        65,368        59,954  

Other assets

     73,962        71,594        57,534  

Goodwill

     340,596        340,596        341,754  

Intangible assets, net

     231,791        236,486        245,724  
  

 

 

    

 

 

    

 

 

 

Total assets

   $ 1,191,390      $ 1,188,970      $ 1,186,881  
  

 

 

    

 

 

    

 

 

 

Liabilities and stockholders’ equity

        

Current liabilities:

        

Accounts payable and accrued expenses

   $ 117,934      $ 118,943      $ 137,512  

Accrued compensation and benefits

     111,984        107,283        107,993  

Current portion of notes payable, less unamortized fees

     —          18,071        3,750  

Deferred revenue

     9,609        9,644        8,924  

Other current liabilities

     5,440        12,387        16,611  
  

 

 

    

 

 

    

 

 

 

Total current liabilities

     244,967        266,328        274,790  

Notes payable, less unamortized fees

     319,652        319,462        359,192  

Deferred income taxes, net

     11,899        12,387        21,420  

Other long-term liabilities

     82,673        82,301        82,096  
  

 

 

    

 

 

    

 

 

 

Total liabilities

     659,191        680,478        737,498  

Commitments and contingencies

        

Stockholders’ equity

     532,199        508,492        449,383  
  

 

 

    

 

 

    

 

 

 

Total liabilities and stockholders’ equity

   $ 1,191,390      $ 1,188,970      $ 1,186,881  
  

 

 

    

 

 

    

 

 

 

 

11


AMN Healthcare Services, Inc.

Summary Condensed Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 30,     June 30,     September 30,  
     2017     2016     2017     2017     2016  

Net cash provided by operating activities

   $ 25,594     $ 29,540     $ 18,474     $ 96,382     $ 84,820  

Net cash used in investing activities

     (3,823     (8,117     (6,320     (23,444     (241,271

Net cash provided by (used in) financing activities

     (24,951     (26,817     (26,945     (63,824     162,418  

Effect of exchange rates on cash

     (73     40       (42     (111     165  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     (3,253     (5,354     (14,833     9,003       6,132  

Cash and cash equivalents at beginning of period

     22,878       21,062       37,711       10,622       9,576  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 19,625     $ 15,708     $ 22,878     $ 19,625     $ 15,708  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

AMN Healthcare Services, Inc.

Additional Supplemental Non-GAAP Disclosures

Reconciliation of Guidance Adjusted EBITDA Margin to

Guidance Operating Margin

(unaudited)

 

     Three Months Ending  
     December 31, 2017  
     Low(11)           High(11)  

Adjusted EBITDA margin

     12.0       12.5

Deduct:

      

Share-based compensation

       0.5  

EBITDA margin

     11.5       12.0
  

 

 

     

 

 

 

Depreciation and amortization

       1.7  
  

 

 

     

 

 

 

Operating margin

     9.8       10.3
  

 

 

     

 

 

 

 

12


(1) Operating margin represents income from operations divided by revenue.
(2) Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, unallocated corporate overhead, acquisition and integration costs and share-based compensation.
(3) Adjusted EBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, acquisition and integration costs and share-based compensation. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that management believes are not indicative of the Company’s operating performance and is a measure used in the Company’s credit agreement and the indenture governing our 5.125% Senior Notes due 2024. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income.
(4) Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
(5) The consolidated effective tax rate for the three and nine months ended September 30, 2017 was favorably affected by the recording of excess tax benefits relating to equity awards vested and exercised during the period. As a result of the adoption of a new accounting pronouncement on January 1, 2017, we no longer record excess tax benefits as an increase to additional paid-in capital, but record such excess tax benefits on a prospective basis as a reduction of income tax expense, which amounted to $56,000 and $5,381,000 for the three and nine months ended September 30, 2017, respectively. Since the majority of our equity awards vest during the first quarter of the year, we do not anticipate the recording of additional excess tax benefits of this magnitude for the reminder of the year. The magnitude of the impact of excess tax benefits generated in the future, which may be favorable or unfavorable, is dependent upon the Company’s future grants of share-based compensation, the Company’s future stock price on the date awards vest or exercise in relation to the fair value of the awards on the grant date or the exercise behavior of the Company’s stock appreciation rights holders. Since these favorable tax benefits are largely unrelated to our current year’s income before taxes and is unrepresentative of our normal effective tax rate, we excluded their impact on adjusted diluted EPS for the three and nine months ended September 30, 2017.
(6) Adjusted diluted EPS represents GAAP diluted EPS excluding the impact of (A) amortization of intangible assets, (B) acquisition and integration costs, (C) tax effect, if any, of the foregoing adjustments, and (D) excess tax benefits relating to equity awards vested and exercised since January 1, 2017. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded from adjusted diluted EPS). Although management believes the items excluded from adjusted diluted EPS are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.
(7) Average healthcare professionals on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period presented.
(8) Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours.
(9) Revenue per day filled represents revenue of the Company’s locum tenens solutions segment divided by days filled for the period presented.
(10) Leverage ratio represents the ratio of the consolidated funded indebtedness (as calculated per the Company’s credit agreement) at the end of the subject period to the consolidated adjusted EBITDA (as calculated per the Company’s credit agreement) for the twelve-month period ended at the end of the subject period.
(11) Guidance percentage metrics are approximate.

 

13